الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 241 |  |  |
| | | from | 241 | | |
Abstract
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders, affectig % to 10% of premenopausal women ‘Solomon, 1999). This syndrome is a spectrum of disorders associated increased androgen production from the ovaries, adrenal ids, or both. The clinical presentation varies to include one or veral of the following features hirsutism, obesity, oligomenorrhea, vu1ation and infertility (Gordon, 1999).
Anovulatory infertility can be a troublesome issue for women PCOS, and multiple management options now exist within the l of reproductive technology for these patients. Wedge resection the ovaries is no longer a first-line therapy and should not be used the treatment of patients with androgen excess, largely because postsurgical complications (Franks, 1995). Infertility treatments ude weight reduction, adrenal suppression, clomiphene citrate, enous gonadotropins, pure FSH, hCG, pulsatile GnRH, and i analogues followed by exogenous gonadotropins (Balen, 1999 recent study also found that metformin treatment resulted in ianced ovulatory response to clomiphene citrate (Nestler et al artia1 ovarian destruction by laparoscopic ovarian diathermy has replaced wedge resection as the surgical therapy for atory women with PCOS. In the first reported series, LOD in ovulation in 90% and conception in 70% of the 62